Aspira Women’s Health (AWHL) takes $1.05M secured subordinated term loan

Q: What new debt did Aspira Women’s Health (AWHL) incur on July 6, 2026?

Aspira Women’s Health entered a Subordinated Business Loan and Security Agreement for a secured term loan. The related Subordinated Secured Promissory Note has $1,050,000 principal, $441,000 scheduled interest charges, and matures on January 26, 2027 , subject to subordination to Senior Indebtedness.

Q: How will Aspira Women’s Health (AWHL) use the proceeds of the new subordinated term loan?

Aspira plans to use the loan proceeds to refinance debt from a loan received in January and for general corporate purposes . This means part of the funds replace existing obligations, while the remainder supports ongoing company activities and needs.

Q: What collateral secures Aspira Women’s Health’s (AWHL) new subordinated loan?

The company and certain subsidiaries granted a continuing security interest in substantially all personal property. This includes goods, accounts, equipment, inventory, general intangibles (including intellectual property), instruments, deposit accounts, investment property, and proceeds, subject to customary exclusions and anti‑assignment limitations where enforceable.

Q: How is Aspira Women’s Health’s (AWHL) new Note ranked relative to other debt?

The Subordinated Secured Promissory Note is expressly subordinated in right of payment to all Senior Indebtedness . In practice, this means senior creditors must be paid in full before amounts under the subordinated Note are paid following specified triggering events.

Q: What happens if Aspira Women’s Health (AWHL) defaults under the subordinated loan agreement?

Events of default include payment and covenant defaults , material adverse changes, certain liens, judgments, and insolvency events. Upon default, lenders may accelerate obligations , exercise remedies under the loan documents and applicable law, and repossess collateral securing the term loan.

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Aspira Women’s Health Inc. entered into a Subordinated Business Loan and Security Agreement with Agile Lending, LLC as lead lender and Agile Capital Funding, LLC as collateral agent. The agreement provides a secured term loan documented by a Subordinated Secured Promissory Note dated as of July 1, 2026.

The Note was issued in a principal amount of $1,050,000, carries scheduled interest charges of $441,000 assuming timely payments, and is scheduled to mature on January 26, 2027. Payment under the Note is expressly subordinated to all Senior Indebtedness. The company and certain subsidiary co‑borrowers granted a continuing security interest in substantially all of their personal property, including goods, accounts, equipment, inventory, general intangibles (including intellectual property), instruments, chattel paper, deposit accounts, other investment property, and related proceeds, subject to customary exclusions. A financing statement may be filed only upon an event of default.

Aspira plans to use the term loan proceeds to refinance debt from a loan received in January and for general corporate purposes. The agreement contains customary affirmative and negative covenants, with certain financial covenant requirements waived, and specifies events of default such as payment failures, covenant breaches, material adverse changes, specified liens, judgments, and insolvency events. Upon default, lenders may accelerate obligations and exercise remedies, including repossession of collateral. The agreement is governed by Virginia law with exclusive jurisdiction in Virginia courts.

8-K Event Classification

3 items: 1.01, 2.03, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial

The company incurred a new significant debt or off-balance-sheet obligation.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Subordinated Note Principal: $1,050,000 Scheduled Interest Charges: $441,000 Loan Maturity Date: January 26, 2027

3 metrics

Subordinated Note Principal $1,050,000 Principal amount of the Subordinated Secured Promissory Note under the term loan

Scheduled Interest Charges $441,000 Total interest charges assuming all payments on the Note are made on time

Loan Maturity Date January 26, 2027 Scheduled maturity date of the Subordinated Secured Promissory Note

Key Terms

Subordinated Business Loan and Security Agreement, Subordinated Secured Promissory Note, Senior Indebtedness, continuing security interest, +1 more

5 terms

Subordinated Business Loan and Security Agreement financial

"entered into a Subordinated Business Loan and Security Agreement"

Subordinated Secured Promissory Note financial

"evidenced by a Subordinated Secured Promissory Note"

Senior Indebtedness financial

"Note is expressly subordinated in right of payment to all Senior Indebtedness"

Senior indebtedness is the portion of a company’s debt that must be repaid before other debts if the company runs into trouble or is liquidated. Think of it like having first dibs on a limited pot of money — lenders holding senior debt are paid first, so their loans are less risky but may carry lower interest. Investors watch senior indebtedness to judge recovery chances and relative risk in a default.

continuing security interest financial

"The Company granted a continuing security interest in substantially all"

material adverse changes financial

"Events of default include payment defaults, certain covenant defaults, material adverse changes"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 07/15/2026 - 04:13 PM Accepted by SEC EDGAR 07/15/2026 - 04:12 PM

FAQ

What new debt did Aspira Women’s Health (AWHL) incur on July 6, 2026?

Aspira Women’s Health entered a Subordinated Business Loan and Security Agreement for a secured term loan. The related Subordinated Secured Promissory Note has $1,050,000 principal, $441,000 scheduled interest charges, and matures on January 26, 2027, subject to subordination to Senior Indebtedness.

How will Aspira Women’s Health (AWHL) use the proceeds of the new subordinated term loan?

Aspira plans to use the loan proceeds to refinance debt from a loan received in January and for general corporate purposes. This means part of the funds replace existing obligations, while the remainder supports ongoing company activities and needs.

What collateral secures Aspira Women’s Health’s (AWHL) new subordinated loan?

The company and certain subsidiaries granted a continuing security interest in substantially all personal property. This includes goods, accounts, equipment, inventory, general intangibles (including intellectual property), instruments, deposit accounts, investment property, and proceeds, subject to customary exclusions and anti‑assignment limitations where enforceable.

How is Aspira Women’s Health’s (AWHL) new Note ranked relative to other debt?

The Subordinated Secured Promissory Note is expressly subordinated in right of payment to all Senior Indebtedness. In practice, this means senior creditors must be paid in full before amounts under the subordinated Note are paid following specified triggering events.

What happens if Aspira Women’s Health (AWHL) defaults under the subordinated loan agreement?

Events of default include payment and covenant defaults, material adverse changes, certain liens, judgments, and insolvency events. Upon default, lenders may accelerate obligations, exercise remedies under the loan documents and applicable law, and repossess collateral securing the term loan.

Which law governs Aspira Women’s Health’s (AWHL) new subordinated loan agreement?

The Subordinated Business Loan and Security Agreement is governed by the laws of the Commonwealth of Virginia. It also provides for exclusive jurisdiction in Virginia courts for disputes arising under the agreement and related documents.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 6, 2026

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)


Delaware		001-34810		33-0595156
(State or other jurisdiction of		(Commission		(IRS Employer
incorporation or organization)		File Number)		Identification No.)

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	AWHL	OTC QX Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On July 6, 2026, Aspira Women’s Health Inc. (the “Company”) entered into a Subordinated Business Loan and Security Agreement (the “Subordinated Loan Agreement”) with Agile Lending, LLC, as lead lender, and Agile Capital Funding, LLC, as collateral agent, pursuant to which the Lenders (as such term is defined in the Subordinary Loan Agreement) agreed to make a secured term loan to the Company and certain subsidiary co-borrowers. The Subordinated Loan Agreement is dated as of July 1, 2026.

The term loan is evidenced by a Subordinated Secured Promissory Note (the “Note”) in the form attached to the Subordinated Loan Agreement. The Note was issued in the principal amount of $1,050,000, will include interest charges of $441,000 (assuming all payments are made on time), and is scheduled to mature on January 26, 2027. The Note is expressly subordinated in right of payment to all Senior Indebtedness, as described in the Note. The Company granted a continuing security interest in substantially all of the Company’s and the co-borrowers’ personal property, including goods, accounts, equipment, inventory, general intangibles (including intellectual property), instruments, chattel paper, deposit accounts and other investment property, and proceeds thereof, in each case subject to customary exclusions (including anti-assignment limitations to the extent enforceable). The collateral agent is authorized to take actions to perfect the security interests; however, the Subordinated Loan Agreement provides that a financing statement may be filed only upon an event of default. The Company will use the proceeds to refinance the Company’s debt related to a loan received in January, as well as for general corporate purposes.

The Subordinated Loan Agreement includes customary affirmative covenants (including financial reporting, maintenance of insurance, and additional assurances) and negative covenants (including restrictions on affiliate transactions), with certain financial covenant requirements waived. Events of default include payment defaults, certain covenant defaults, material adverse changes, certain liens, judgments, and insolvency events, among others. Upon an event of default, the lenders may accelerate the obligations, exercise remedies under the loan documents and applicable law, and repossess collateral. The Subordinated Loan Agreement is governed by the laws of the Commonwealth of Virginia, with exclusive jurisdiction in Virginia courts as specified in the agreement.

The description of the Subordinary Loan Agreement, the Note and related documents is qualified in its entirety by reference to the full text of such agreements, copies of which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and which are incorporated by reference herein.

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03 to the extent it relates to the creation of a direct financial obligation.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.


Exhibit No.		Description
10.1		Subordinated Business Loan and Security Agreement, dated as of July 1, 2026.
10.2		Form of Subordinated Secured Promissory Note (included as Exhibit D to the Subordinated Business Loan and Security Agreement filed as Exhibit 10.1 hereto).
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: July 15, 2026


	ASPIRA WOMEN’S HEALTH INC.

	By:	/s/ John Strahley
	Name:	John Strahley
	Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Agreements & Contracts

EX-10.1 EX-10.1 466.7 KB